Status In progress
Process HST
ID number 861

Project Team

Project lead Joanne Ekeledo

Email enquiries


Companies sponsors Aegerion Pharmaceuticals Ltd
Others Department of Health
  NHS England
Patient carer groups Diabetes UK
  Lipodystrophy UK
Professional groups Royal College of Physicians


Comparator companies None
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Health Improvement Scotland
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee


Key events during the development of the guidance:

Date Update
21 June 2019 - 05 July 2019 Final evaluation determination
12 February 2019 Committee meeting: 2
14 August 2018 The forthcoming committee meeting to discuss metreleptin for treating lipodystrophy on Wednesday 24 October 2018 has been rearranged to enable the company to prepare and submit additional information for committees consideration. Metreleptin for treating lipodystrophy will be now considered by committee on Tuesday 12 February 2019.
23 July 2018 - 13 August 2018 Evaluation consultation: 1
28 June 2018 Committee meeting: 1
08 November 2017 Invitation to participate
21 April 2017 Referral
21 April 2017 In progress, Topic referred
21 November 2016 - 19 December 2016 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE highly specialised technologies guidance